FGFR4 Gly388Arg polymorphism contributes to prostate cancer development and progression: A meta-analysis of 2618 cases and 2305 controls

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Xu, Bin ^a   Tong, Na ^b   Chen, Shu Q ^a   Hua, Li X ^c   Wang, Zeng J ^c   Zhang, Zheng D ^b   Chen, Ming ^a  

^a AFFILIATED ZHONGDA HOSPITAL OF SOUTHEAST UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

^c THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; FIBROBLAST GROWTH FACTOR RECEPTOR 4; GLYCINE; FGFR4 PROTEIN, HUMAN; TUMOR MARKER;

ADVANCED CANCER; ALLELE; ARTICLE; CANCER GROWTH; CANCER RISK; CARCINOGENESIS; CONTROLLED STUDY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; PROSTATE CANCER; QUANTITATIVE ANALYSIS; RACE DIFFERENCE; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; AMINO ACID SUBSTITUTION; CARCINOMA; CASE CONTROL STUDY; CELL TRANSFORMATION; DISEASE COURSE; GENETICS; MALE; META ANALYSIS; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR; SINGLE NUCLEOTIDE POLYMORPHISM;

AMINO ACID SUBSTITUTION; ARGININE; CARCINOMA; CASE-CONTROL STUDIES; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; GLYCINE; HUMANS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 4; TUMOR MARKERS, BIOLOGICAL;

EID: 79951947756     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-84     Document Type: Article

References (23)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009, 59(4):225-249. 10.3322/caac.20006, 19474385.
2. Wilkie AO, Morriss-Kay GM, Jones EY, Heath JK. Functions of fibroblast growth factors and their receptors. Curr Biol 1995, 5(5):500-507. 10.1016/S0960-9822(95)00102-3, 7583099.
3. Powers CJ, McLeskey SW, Wellstein A. Fibroblast growth factors, their receptors and signaling. Endocr Relat Cancer 2000, 7(3):165-197. 10.1677/erc.0.0070165, 11021964.
4. Sahadevan K, Darby S, Leung HY, Mathers ME, Robson CN, Gnanapragasam VJ. Selective over-expression of fibroblast growth factor receptors 1 and 4 in clinical prostate cancer. J Pathol 2007, 213(1):82-90. 10.1002/path.2205, 17607666.
5. Gowardhan B, Douglas DA, Mathers ME, McKie AB, McCracken SR, Robson CN, Leung HY. Evaluation of the fibroblast growth factor system as a potential target for therapy in human prostate cancer. Br J Cancer 2005, 92(2):320-327. 2361833, 15655558.
6. Bange J, Prechtl D, Cheburkin Y, Specht K, Harbeck N, Schmitt M, Knyazeva T, Muller S, Gartner S, Sures I, et al. Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. Cancer Res 2002, 62(3):840-847.
7. Morimoto Y, Ozaki T, Ouchida M, Umehara N, Ohata N, Yoshida A, Shimizu K, Inoue H. Single nucleotide polymorphism in fibroblast growth factor receptor 4 at codon 388 is associated with prognosis in high-grade soft tissue sarcoma. Cancer 2003, 98(10):2245-2250. 10.1002/cncr.11778, 14601095.
8. FitzGerald LM, Karlins E, Karyadi DM, Kwon EM, Koopmeiners JS, Stanford JL, Ostrander EA. Association of FGFR4 genetic polymorphisms with prostate cancer risk and prognosis. Prostate Cancer Prostatic Dis 2009, 12(2):192-197. 10.1038/pcan.2008.46, 2790323, 18762813.
9. Ho CK, Anwar S, Nanda J, Habib FK. FGFR4 Gly(388)Arg polymorphism and prostate cancer risk in Scottish men. Prostate Cancer Prostatic Dis 2009,
10. Ma Z, Tsuchiya N, Yuasa T, Inoue T, Kumazawa T, Narita S, Horikawa Y, Tsuruta H, Obara T, Saito M, et al. Polymorphisms of fibroblast growth factor receptor 4 have association with the development of prostate cancer and benign prostatic hyperplasia and the progression of prostate cancer in a Japanese population. Int J Cancer 2008, 123(11):2574-2579. 10.1002/ijc.23578, 18756523.
11. Wang J, Stockton DW, Ittmann M. The fibroblast growth factor receptor-4 Arg388 allele is associated with prostate cancer initiation and progression. Clin Cancer Res 2004, 10(18 Pt 1):6169-6178. 10.1158/1078-0432.CCR-04-0408, 15448004.
12. Wang J, Yu W, Cai Y, Ren C, Ittmann MM. Altered fibroblast growth factor receptor 4 stability promotes prostate cancer progression. Neoplasia 2008, 10(8):847-856. 2481572, 18670643.
13. Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med 1997, 127(9):820-826.
14. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7(3):177-188. 10.1016/0197-2456(86)90046-2, 3802833.
15. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959, 22(4):719-748.
16. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994, 50(4):1088-1101. 10.2307/2533446, 7786990.
17. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. Bmj 1997, 315(7109):629-634. 2127453, 9310563.
18. Spinola M, Leoni V, Pignatiello C, Conti B, Ravagnani F, Pastorino U, Dragani TA. Functional FGFR4 Gly388Arg polymorphism predicts prognosis in lung adenocarcinoma patients. J Clin Oncol 2005, 23(29):7307-7311. 10.1200/JCO.2005.17.350, 16061909.
19. Dorkin TJ, Robinson MC, Marsh C, Bjartell A, Neal DE, Leung HY. FGF8 over-expression in prostate cancer is associated with decreased patient survival and persists in androgen independent disease. Oncogene 1999, 18(17):2755-2761. 10.1038/sj.onc.1202624, 10348350.
20. Heer R, Douglas D, Mathers ME, Robson CN, Leung HY. Fibroblast growth factor 17 is over-expressed in human prostate cancer. J Pathol 2004, 204(5):578-586. 10.1002/path.1668, 15538740.
21. Zhang X, Ibrahimi OA, Olsen SK, Umemori H, Mohammadi M, Ornitz DM. Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. J Biol Chem 2006, 281(23):15694-15700. 10.1074/jbc.M601252200, 2080618, 16597617.
22. Desnoyers LR, Pai R, Ferrando RE, Hotzel K, Le T, Ross J, Carano R, D'Souza A, Qing J, Mohtashemi I, et al. Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models. Oncogene 2008, 27(1):85-97. 10.1038/sj.onc.1210623, 17599042.
23. Bai JL, Zheng MH, Xia X, Ter-Minassian M, Chen YP, Chen F. MTHFR C677T polymorphism contributes to prostate cancer risk among Caucasians: A meta-analysis of 3511 cases and 2762 controls. Eur J Cancer 2009, 45(8):1443-1449. 10.1016/j.ejca.2009.01.020, 19223177.